CANO - Cano Health, Inc. Stock Price, Fair Value and News

0.23USD Market Closed

Market Summary

USD0.23

Market Closed

CANO Stock Price

View Fullscreen

CANO RSI Chart

CANO Valuation

Market Cap

1.1M

Price/Earnings (Trailing)

Price/Sales (Trailing)

4e-4

EV/EBITDA

0.13

Price/Free Cashflow

-0.01

CANO Price/Sales (Trailing)

CANO Profitability

EBT Margin

-51.38%

Return on Equity

97.3%

Return on Assets

-93.92%

Free Cashflow Yield

-15.5K%

CANO Fundamentals

CANO Revenue

Revenue (TTM)

3.0B

Rev. Growth (Yr)

-21.05%

Rev. Growth (Qtr)

-4.41%

CANO Earnings

Earnings (TTM)

-982.0M

Earnings Growth (Yr)

-1.4K%

Earnings Growth (Qtr)

-151.9%

Breaking Down CANO Revenue

Last 7 days

4.6%

Last 30 days

-14.8%

Last 90 days

-94.2%

Trailing 12 Months

-81.6%

How does CANO drawdown profile look like?

CANO Financial Health

Current Ratio

0.96

CANO Investor Care

Shares Dilution (1Y)

91.63%

Diluted EPS (TTM)

-318.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.0B	0	0	0
2023	2.9B	3.0B	3.1B	3.1B
2022	2.0B	2.4B	2.6B	2.7B
2021	970.9M	1.1B	1.4B	1.6B
2020	0	518.1M	674.8M	831.6M
2019	0	0	0	361.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cano Health, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	cooperstone elliot	sold	-2,780	2.5277	-1,100	-
Jan 31, 2024	cooperstone elliot	sold	-23,177	2.594	-8,935	-
Jan 30, 2024	cooperstone elliot	sold	-34,285	2.699	-12,703	-
Jan 29, 2024	cooperstone elliot	sold	-113,471	2.7437	-41,357	-
Jan 26, 2024	cooperstone elliot	sold	-89,735	2.7448	-32,693	-
Jan 25, 2024	cooperstone elliot	sold	-47,960	2.5828	-18,569	-
Jan 24, 2024	cooperstone elliot	sold	-101,612	2.8377	-35,808	-
Jan 23, 2024	cooperstone elliot	sold	-214,800	2.9411	-73,034	-
Jan 22, 2024	cooperstone elliot	sold	-312,762	2.5021	-125,000	-
Jan 18, 2024	cooperstone elliot	sold	-191,250	1.9125	-100,000	-

Which funds bought or sold CANO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Global Financial Private Client, LLC	unchanged	-	-1,119	43.00	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	sold off	-100	-2,518	-	-%
May 15, 2024	DEUTSCHE BANK AG\	sold off	-100	-299	-	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-254,071	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-149,644	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-77,719	-	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-	-	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-21,000	-	-%
May 15, 2024	JOSH ARNOLD INVESTMENT CONSULTANT, LLC	sold off	-100	-254	-	-%
May 15, 2024	Corton Capital Inc.	sold off	-100	-71,103	-	-%

Are Funds Buying or Selling CANO?

Are funds buying CANO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CANO

No. of Funds

Unveiling Cano Health, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.33%	125,122	SC 13G/A
Feb 07, 2024	cooperstone elliot	11.5%	516,007	SC 13D/A
Jan 29, 2024	blackrock inc.	6.1%	176,830	SC 13G
Jan 26, 2024	cooperstone elliot	12.9%	580,102	SC 13D/A
Jan 12, 2024	cooperstone elliot	23.7%	1,065,206	SC 13D/A
Dec 29, 2023	cooperstone elliot	30.0%	1,346,210	SC 13D/A
Dec 21, 2023	hernandez marlow	4.39%	237,236	SC 13D/A
Dec 19, 2023	cooperstone elliot	35.6%	1,597,809	SC 13D/A
Nov 20, 2023	d. e. shaw & co, l.p.	5.2%	149,579	SC 13G
Nov 07, 2023	cooperstone elliot	-	0	SC 13D/A

Recent SEC filings of Cano Health, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report
Apr 04, 2024	SC 13D/A	13D - Major Acquisition
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	10-K	Annual Report
Mar 29, 2024	EFFECT	EFFECT

Peers (Alternatives to Cano Health, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

Cano Health, Inc. News

Latest updates

Cano Health, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-4.4%	684,426,000	716,028,500	788,073,000	766,746,000	866,909,000	680,275,500	665,028,000	689,373,000	704,337,000	492,255,000	498,931,000	343,581,000	274,602,000	261,939,000	263,133,000	171,206,000	-
Operating Expenses	-17.8%	795,536,000	968,374,500	1,254,992,000	1,012,380,000	906,438,000	71,652,000	696,473,000	720,422,000	715,793,000	534,512,000	532,523,000	398,145,000	279,377,000	332,221,294	256,520,000	176,117,000	-
S&GA Expenses	3.5%	89,109,000	86,098,000	80,821,000	99,418,000	96,473,000	2,122,000	111,765,000	106,179,000	96,587,000	93,347,000	76,618,000	47,159,000	35,009,000	33,728,000	27,391,000	21,859,000	-
EBITDA Margin	-58.7%	-0.44	-0.28	-0.30	-0.19	-0.12	-0.11	0.01	0.02	0.01	-0.01	-0.06	-0.04	-0.02	-0.02	0.00	-0.01	-0.01
Interest Expenses	-57.3%	14,900,000	34,882,500	29,646,000	26,719,000	23,500,000	19,618,500	16,451,000	13,134,000	13,300,000	14,922,500	16,023,000	9,714,000	10,600,000	12,300,000	12,346,000	5,700,000	-
Income Taxes	-80.7%	40,000	207,500	-145,000	-1,900,000	-	1,516,000	-1,248,000	809,000	1,080,000	776,000	547,000	-2,023,000	714,000	357,000	326,000	-19,000	-
Earnings Before Taxes	-73.5%	-478,169,000	-275,674,000	-491,842,000	-272,617,000	-60,585,000	-300,213,000	-113,259,000	-13,755,000	995,000	1,280,500	-64,293,000	-38,312,000	-15,400,000	-46,418,000	-10,791,000	-11,005,000	-
EBT Margin	-46.5%	-0.51	-0.35	-0.36	-0.25	-0.17	-0.16	-0.05	-0.03	-0.05	-0.07	-0.12	-0.10	-0.09	-0.08	-0.03	-0.04	-0.05
Net Income	-151.9%	-415,706,000	-165,028,000	-260,487,000	-140,753,000	-28,150,000	299,000	-54,228,000	-5,333,000	660,000	8,719,000	-23,238,000	4,555,000	-16,114,000	-47,866,293	-11,117,000	-10,986,000	-
Net Income Margin	-75.4%	-0.33	-0.19	-0.14	-0.07	-0.03	-0.02	-0.02	-0.01	0.00	-0.02	-0.06	-0.06	-0.09	-0.08	-0.03	-0.04	-0.05
Free Cashflow	-9.2%	-49,642,000	-45,477,000	-46,535,000	-21,720,000	-34,550,000	-72,647,000	-20,615,000	-57,625,000	-44,979,000	-34,673,000	-51,884,000	-48,497,000	-17,333,000	9,178,000	-13,371,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	3.1%	1,046	1,014	1,212	1,707	1,944	1,929	2,196	2,141	2,172	2,144	2,140	1,659	691	614	692	693	-	-
Current Assets	39.5%	255	183	145	166	314	341	305	287	324	317	465	472	1.00	111	2.00	2.00	-	-
Cash Equivalents	134.9%	178	76.00	41.00	28.00	45.00	27.00	24.00	48.00	113	163	209	319	7.00	34.00	27.00	11.00	-	29.00
Inventory	-	-	-	-	-	-	-	-	-	-	1.00	2.00	1.00	-	1.00	-	-	-	-
Net PPE	-	-	-	-	-	-	-	126	106	96.00	85.00	64.00	46.00	-	38.00	-	-	-	-
Goodwill	-	-	-	89.00	480	480	480	788	777	773	770	766	151	-	234	90.00	90.00	-	14.00
Liabilities	32.7%	2,055	1,549	1,471	1,472	1,440	1,435	1,413	1,300	1,334	1,345	1,282	771	134	565	24.00	24.00	-	-
Current Liabilities	-81.1%	267	1,415	366	337	214	208	186	142	159	161	140	93.00	3.00	67.00	0.00	0.00	0.00	0.00
Shareholder's Equity	-88.6%	-1,009	-535	-	236	504	253	783	841	838	799	780	834	34.00	50.00	207	224	111	87.00
Retained Earnings	-47.2%	-1,296	-880	-715	-454	-314	-286	-137	-83.43	-78.10	-78.76	-52.55	-37.64	-47.02	-107	-7.11	-2.57	-0.01	-0.01
Additional Paid-In Capital	-22.3%	414	532	593	602	595	539	544	496	464	397	363	390	52.00	-	12.00	8.00	0.00	-
Shares Outstanding	66.9%	5.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	0.00	-
Minority Interest	32.1%	-126	-187	-137	89.00	224	242	377	429	452	480	547	536	-	-	-	-	-	-
Float	-	-	-	-	339	-	-	-	1,152	-	-	-	2,749	-	-	-	925	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-10.0%	-48.83	-44.38	-39.67	-15.53	-29.47	-62.18	-1.98	-44.97	-37.20	-23.54	-36.39	-43.41	-14.69	12.00	-7.90	-	-
Share Based Compensation	347.4%	4.00	1.00	-4.08	2.00	9.00	12.00	11.00	18.00	14.00	15.00	9.00	4.00	0.00	0.00	0.00	-	-
Cashflow From Investing	83.1%	4.00	2.00	27.00	-8.24	-9.46	-16.00	-18.88	-15.82	-13.46	-18.40	-466	-636	-9.70	-14.81	-7.63	-	-
Cashflow From Financing	91.9%	147	77.00	27.00	7.00	56.00	81.00	-2.88	-4.42	1.00	-3.80	393	992	-2.82	9.00	32.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CANO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenue:

Total revenue

$ 684,426

$ 866,909

Operating expenses:

Third-party medical costs

640,991

708,331

Direct patient expense (Related parties comprised $0 and $4,115 in the three months ended March 31, 2024 and 2023, respectively)

45,865

68,427

Selling, general, and administrative expenses (Related parties comprised $(304) and $1,327 in the three months ended March 31, 2024 and 2023, respectively)

89,109

96,473

Depreciation and amortization expense

18,371

27,221

Transaction costs

1,200

10,086

Change in fair value of contingent consideration

(4,100)

Total operating expenses

795,536

906,438

Income (loss) from operations

(111,110)

(39,529)

Other income (expense):

Interest expense (excludes $22,093 of contractual interest for the three months ended March 31, 2024)

(14,930)

(23,505)

Interest income

497

Change in fair value of warrant liabilities

2,008

Other income (expense)

(10,715)

432

Total other income (expense)

(25,148)

(21,056)

Reorganization items, net

(341,911)

Net income (loss) before income tax expense

(478,169)

(60,585)

Income tax (expense) benefit

(36)

Net income (loss)

(478,205)

(60,585)

Net income (loss) attributable to non-controlling interests

(62,499)

(32,435)

Net income (loss) attributable to Class A common stockholders

^[1]

$ (415,706)

$ (28,150)

Net income (loss) per share attributable to Class A common stockholders, basic (in dollars per share)

^[1]

$ (90.46)

$ (11.74)

Net income (loss) per share attributable to Class A common stockholders, diluted (in dollars per share)

^[1]

$ (91.10)

$ (12.03)

Weighted-average shares outstanding

Basic (in shares)

^[1]

4,595,364

2,398,021

Diluted (in shares)

^[1]

5,249,007

5,034,402

Capitated revenue

Revenue:

Total revenue

$ 669,075

$ 841,074

Fee-for-service and other revenue

Revenue:

Total revenue

$ 15,351

$ 25,835

[1]	Weighted-average shares outstanding and per-share amounts for all periods reflect the 1-for-100 Reverse Stock Split that the Company completed on November 3, 2023.

CANO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash, cash equivalents and restricted cash

$ 177,993

$ 75,763

Accounts receivable, net of unpaid service provider costs

54,218

75,801

Equity securities at fair value

1,400

18,160

Prepaid expenses and other current assets

21,470

13,099

Total current assets

255,081

182,823

Property and equipment, net

47,578

54,641

Operating lease right-of-use assets

60,035

78,458

Payor relationships, net

517,758

525,511

Other intangibles, net

160,913

167,453

Other assets

4,181

4,853

Total assets

1,045,546

1,013,739

Current liabilities:

Accounts payable and accrued expenses (Related parties comprised $6,973 and $6,239 as of March 31, 2024 and December 31, 2023, respectively)

60,116

108,347

Current portion of notes payable, net of debt issuance costs

183,750

1,157,318

Current portion of finance lease liabilities

2,734

3,196

Current portions due to sellers

48,221

Current portion of operating lease liabilities

13,653

22,750

Other current liabilities

6,745

75,594

Total current liabilities

266,998

1,415,426

Long term portion of operating lease liabilities

61,725

124,329

Long term portion of finance lease liabilities

5,841

7,044

Other liabilities

1,941

Liabilities subject to compromise

1,720,188

Total liabilities

2,054,752

1,548,740

Stockholders’ Deficit

Additional paid-in capital

^[1]

413,881

532,424

Accumulated deficit

^[1]

(1,296,156)

(880,450)

Total Stockholders' Deficit before non-controlling interests

^[1]

(882,222)

(347,973)

Non-controlling interests

(126,984)

(187,028)

Total Stockholders' Deficit

(1,009,206)

(535,001)

Total Liabilities and Stockholders' Deficit

1,045,546

1,013,739

Class A common stock

Stockholders’ Deficit

Common stock

^[1]

Class B common stock

Stockholders’ Deficit

Common stock

^[1]

$ 7

$ 18

[1]	Authorized and outstanding share and per-share amounts for all periods reflect the 1-for-100 Reverse Stock Split that the Company completed on November 3, 2023.

About Cano Health, Inc.

Cano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.

CEO	Mr. Mark Kent
WEBSITE	https://canohealth.com
INDUSTRY	Healthcare Plans
EMPLOYEES	4118

Cano Health, Inc. Frequently Asked Questions

What is the ticker symbol for Cano Health, Inc.? What does CANO stand for in stocks?

CANO is the stock ticker symbol of Cano Health, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cano Health, Inc. (CANO)?

As of Fri Apr 05 2024, market cap of Cano Health, Inc. is 1.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CANO stock?

You can check CANO's fair value in chart for subscribers.

What is the fair value of CANO stock?

You can check CANO's fair value in chart for subscribers. The fair value of Cano Health, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cano Health, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CANO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cano Health, Inc. a good stock to buy?

The fair value guage provides a quick view whether CANO is over valued or under valued. Whether Cano Health, Inc. is cheap or expensive depends on the assumptions which impact Cano Health, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CANO.

What is Cano Health, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 05 2024, CANO's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CANO PE ratio will change depending on the future growth rate expectations of investors.